Emergency Use Authorization (EUA) from the US FDA. 
The COVID-19 IgG/IgM (Whole Blood/Serum/Plasma) Rapid Test Device utilizes lateral flow technology that is used for the qualitative, differential detection of both anti-SARS-CoV-2 IgM and IgG antibodies. In general, antibodies can be detected 1-3 weeks after infection. This test is intended to screen patients for COVID-19. Combining RNA and Antibody tests can significantly raise the sensitivity for detecting COVID-19 in infected individuals.
​
Coronaviruses are enveloped RNA viruses that are distributed broadly among humans, other mammals and birds that cause respiratory, enteric, hepatic and neurologic diseases. Four viruses - 229E, OC43, NL63 and HKU1 are prevalent and typically cause common cold symptoms in immunocompromised individuals. Three other strains SARS-CoV, MERS-CoV and SARS-CoV-2 (COVID-19) are can be transmitted from between non-human vertebrates to humans.
 
	
	
Detection Window (IgM): 3-5 days after incubation 
	
	
	
Dual band results for simple interpretation
	
	
	
Multivariable analysis of immunoglobin IgG & IgM
	
	
	
Room temperature storage or refrigerated (2-30⁰C / 36-86⁰F)
	
	
	
Procedural internal control included
	
	
	
Buffer included
	
 
Tests should only be conducted by a medical professional.
 
**Due to FDA Guidelines and Supply Chain Demands All Coronaviruses COVID-19 Related Orders and/or Products are NON-Cancellable and NON-Returnable.**